Business Context and Reporting Period
Company: pSivida Corp. (Note: Input metadata referenced "Eyepoint, Inc.", but the filing text identifies the registrant as pSivida Corp.)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2009
Business Overview: pSivida develops sustained-release drug delivery products for chronic eye diseases and cancer. The company operates primarily through strategic collaborations rather than direct sales. Key technologies include Durasert (for ophthalmic implants), BioSilicon (for cancer treatment), and CODRUG. Major partners include Alimera Sciences (Iluvien), Bausch & Lomb (Retisert, Vitrasert), and Pfizer.
Key Financial Metrics
| Metric | Fiscal 2009 | Fiscal 2008 | Fiscal 2007 |
|---|---|---|---|
| Total Revenue | $12.2 million | $3.5 million | $1.8 million |
| Net Loss | $(2.5) million | $(75.7) million | $(81.2) million |
| Operating Expenses | $16.8 million | $88.5 million | $77.5 million |
| Cash and Cash Equivalents | $6.9 million | $15.6 million | $2.7 million |
| Accumulated Deficit | $(227.0) million | $(224.5) million | $(148.9) million |
| Intangible Assets (Net) | $28.8 million | $36.8 million | $64.3 million |
Revenue Composition (2009): Collaborative research and development revenue was $12.0 million (primarily from Alimera); Royalty income was $0.2 million.
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased 250% to $12.2 million, driven by the recognition of $11.8 million in revenue from the amended collaboration agreement with Alimera (March 2008).
- Significant Loss Reduction: Net loss decreased by 97% to $2.5 million. This improvement is largely due to the absence of a $60.1 million goodwill impairment charge recorded in fiscal 2008 and a $45.3 million intangible asset impairment in fiscal 2007.
- Expense Reduction: Operating expenses dropped 81% to $16.8 million. Research and Development (R&D) expenses fell 44% to $8.0 million, primarily because Alimera assumed financial responsibility for Iluvien development costs. General and Administrative (G&A) expenses fell 37% to $8.8 million, aided by the absence of one-time reincorporation costs.
- Cash Position: Cash and cash equivalents decreased by $8.7 million to $6.9 million, reflecting net cash used in operating activities of $8.4 million.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes cash reserves ($6.9 million) are sufficient to fund operations through at least December 31, 2010. This projection relies on continued quarterly funding from Pfizer ($500,000/quarter) and scheduled payments from Alimera.
- Product Pipeline:
- Iluvien (Alimera): Phase III trials for Diabetic Macular Edema (DME) are fully recruited. Interim data expected late 2009; NDA filing anticipated early 2010. A $25 million milestone payment is due upon FDA approval.
- BrachySil (BioSilicon): Phase II dose-ranging trials for pancreatic cancer are nearing completion. The company seeks a development partner before Phase III.
- Retisert (Bausch & Lomb): Royalty payments are currently suspended as Bausch & Lomb retains royalties to recoup a $3.0 million advance. Resumption is not expected until at least Q4 fiscal 2010.
- Key Risks:
- Capital Needs: Future funding beyond late 2010 is uncertain and dependent on Iluvien approval or new financing, which may be dilutive.
- Partner Dependency: The company relies entirely on partners (Alimera, Bausch & Lomb, Pfizer) for development, marketing, and sales. Partners can terminate agreements with 90 days' notice.
- Derivative Liabilities: The company has outstanding warrants denominated in Australian Dollars, creating derivative liabilities subject to fair value adjustments based on stock price volatility.
Investor Verification Checklist
- Alimera Collaboration Status: Verify the progress of Iluvien Phase III trials and the likelihood of the early 2010 NDA filing, as this triggers a $25 million milestone and future profit sharing.
- Cash Runway: Confirm the company's ability to meet the December 2010 liquidity horizon without raising additional capital, given the reliance on partner payments.
- Retisert Royalties: Monitor Bausch & Lomb sales data to determine when the $3.0 million advance is fully recouped and royalty payments to pSivida resume.
- Derivative Liability Exposure: Assess the impact of pSivida's stock price volatility on the $0.97 million derivative liability balance and future earnings.
- Intangible Asset Valuation: Review the remaining $28.8 million in intangible assets (BioSilicon and Retisert) for potential future impairment risks if commercialization timelines slip.